Antitrust considerations now a much bigger factor in pharma patent dealmaking
Following recent forced divestments - and with growing political concern about life sciences acquisitions - the signs are that regulators will play a larger role in transactions
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.